A5320: Viral Hepatitis C Infection Long-term Cohort Study (V-HICS)

Study Location:

Baltimore

Topic:

Hepatitis and HIV

Clinicaltrials.gov Link:

N/A

IRB#:

NA_00092078

Coordinator:

Ilene Wiggins, RN (Baltimore)

Anna Wimpelberg (Washington)

Enrollment:

Closed

Trial Period:

Ongoing

A5320/V-HICS is an observational, prospective, long-term follow-up study in hepatitis C virus (HCV) monoinfected and HCV/HIV-1 coinfected participants who received direct-acting antiviral (DAA) therapy for HCV infection.

Men and women ≥ 18 years old, HCV/HIV-1 coinfected who failed HCV therapy any time after HCV/DAA treatment discontinuation (non-SVR); or HCV monoinfected who failed HCV therapy any time after HCV/DAA treatment discontinuation (non-SVR); or HCV/HIV-1 coinfected participants who achieved a SVR at least 12 weeks after treatment completion; or HCV monoinfected participants who achieved a SVR as at least 12 weeks after treatment completion.

Anna Wimpelberg (Washington)
202-797-3589
awimpelberg@whitman-walker.org


​Ilene Wiggins, RN (Baltimore)
410-614-2766
iwiggin1@jhmi.edu

Categories

Location
Topic

Clinical Trials

NWCS 414, Evaluation of a Serum Biosignature for Identifying...

We will address our hypothesis using a case-control study design. We plan to leverage the existing biorepository of...

Read More

A5350: Effects of Visbiome Extra Strength on Gut Microbiome...

Many factors contribute to the development of aging-related conditions, including gastrointestinal (GI) diseases, such as...

Read More

A5314: Effect of LDMTX on Inflammation in HIV-infected...

A5314 is a phase II randomized, double-blind, placebo-controlled 36-week trial that will examine the safety and efficacy of...

Read More

A5300B/I2003B/PHOENIX, Protecting Households On Exposure to...

This study will compare the efficacy and safety of 26 weeks of delamanid (DLM) versus 26 weeks of isoniazid (INH) for preventing...

Read More

A5273: Multicenter Study of Options for Second-Line...

The study is being done with people who are taking their first anti-HIV drug regimen (including an Non-Nucleoside Reverse...

Read More